Compare Stocks: MNOV, ZNTL, ACB, and NMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.95 +1.5%	$3.18	$2.56 ▼ $6.66	$252.24M	0.63	1.87 million shs	691,170 shs
MNOV MediciNova	$1.63 +0.6%	$1.38	$1.17 ▼ $1.96	$79.74M	0.63	40,141 shs	96,718 shs
NMRA Neumora Therapeutics	$1.31 -3.0%	$1.59	$0.83 ▼ $3.65	$246.14M	2.71	705,403 shs	546,973 shs
ZNTL Zentalis Pharmaceuticals	$3.99 -2.9%	$4.37	$1.21 ▼ $6.95	$285.97M	1.85	1.14 million shs	997,785 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	+1.54%	-1.50%	+36.44%	+16.86%	-19.55%
MNOV MediciNova	+0.62%	+13.59%	+22.56%	+24.43%	+23.48%
NMRA Neumora Therapeutics	-2.96%	-5.76%	-18.63%	-19.63%	-25.14%
ZNTL Zentalis Pharmaceuticals	-2.92%	+5.00%	-19.39%	+9.02%	+133.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.95 +1.5%	$3.18	$2.56 ▼ $6.66	$252.24M	0.63	1.87 million shs	691,170 shs
MNOV MediciNova	$1.63 +0.6%	$1.38	$1.17 ▼ $1.96	$79.74M	0.63	40,141 shs	96,718 shs
NMRA Neumora Therapeutics	$1.31 -3.0%	$1.59	$0.83 ▼ $3.65	$246.14M	2.71	705,403 shs	546,973 shs
ZNTL Zentalis Pharmaceuticals	$3.99 -2.9%	$4.37	$1.21 ▼ $6.95	$285.97M	1.85	1.14 million shs	997,785 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	+1.54%	-1.50%	+36.44%	+16.86%	-19.55%
MNOV MediciNova	+0.62%	+13.59%	+22.56%	+24.43%	+23.48%
NMRA Neumora Therapeutics	-2.96%	-5.76%	-18.63%	-19.63%	-25.14%
ZNTL Zentalis Pharmaceuticals	-2.92%	+5.00%	-19.39%	+9.02%	+133.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.50	Moderate Buy	N/A	N/A
MNOV MediciNova	2.67	Moderate Buy	$8.33	411.25% Upside
NMRA Neumora Therapeutics	2.60	Moderate Buy	$6.57	401.64% Upside
ZNTL Zentalis Pharmaceuticals	2.33	Hold	$6.75	69.17% Upside

Current Analyst Ratings Breakdown

Latest MNOV, ZNTL, ACB, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/11/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/5/2026	ACB Aurora Cannabis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/28/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/17/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ZNTL Zentalis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$314.07M	0.82	$0.71 per share	5.54	$5.87 per share	0.67
MNOV MediciNova	$410K	195.68	N/A	N/A	$0.76 per share	2.14
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.24 per share	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	$2.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	65.83	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
MNOV MediciNova	-$12M	-$0.21	N/A	N/A	N/A	-1,168.70%	-26.51%	-24.39%	11/12/2026 (Estimated)
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)

Latest MNOV, ZNTL, ACB, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/13/2026	Q2 2026	MNOV MediciNova	-$0.0633	-$0.05	+$0.0133	-$0.05	$0.08 million	$0.46 million
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million
6/11/2026	Q4 2026	ACB Aurora Cannabis	-$0.07	$0.07	+$0.14	$0.86	$54.42 million	$60.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
MNOV MediciNova	N/A	8.75	8.75
NMRA Neumora Therapeutics	1.19	4.50	4.50
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
MNOV MediciNova	9.90%
NMRA Neumora Therapeutics	47.65%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
MNOV MediciNova	14.00%
NMRA Neumora Therapeutics	26.94%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	64.84 million	64.84 million	Optionable
MNOV MediciNova	10	49.22 million	42.33 million	Optionable
NMRA Neumora Therapeutics	108	187.90 million	137.28 million	Optionable
ZNTL Zentalis Pharmaceuticals	160	71.67 million	68.95 million	Optionable

MNOV, ZNTL, ACB, and NMRA Headlines

Recent News About These Companies

BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL

September 4 at 3:28 AM | marketbeat.com

Zentalis to present at Wells Fargo, Morgan Stanley events

September 2 at 5:46 PM | msn.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

September 2 at 4:05 PM | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

August 31, 2026 | seekingalpha.com

Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

August 29, 2026 | marketbeat.com

Primecap Management Co. CA Takes $4.64 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 27, 2026 | marketbeat.com

652,750 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

3,947,913 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by 5AM Venture Management LLC

August 26, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Acquires 4,335,000 Shares

August 20, 2026 | insidertrades.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock

August 19, 2026 | marketbeat.com

Zentalis Pharma closes $92.6 million public offering

August 19, 2026 | thepharmaletter.comT

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17, 2026 | markets.businessinsider.com

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 17, 2026 | globenewswire.com

GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL

August 17, 2026 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

August 16, 2026 | marketbeat.com

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

August 14, 2026 | msn.com

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

August 13, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

August 13, 2026 | globenewswire.com

HC Wainwright Analysts Decrease Earnings Estimates for ZNTL

August 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MNOV, ZNTL, ACB, and NMRA Company Descriptions

Aurora Cannabis NASDAQ:ACB

$3.95 +0.06 (+1.54%)

As of 09/4/2026 04:00 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

MediciNova NASDAQ:MNOV

$1.63 +0.01 (+0.62%)

As of 09/4/2026 04:00 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Neumora Therapeutics NASDAQ:NMRA

$1.31 -0.04 (-2.96%)

As of 09/4/2026 04:00 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$3.99 -0.12 (-2.92%)

As of 09/4/2026 04:00 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNOV, ZNTL, ACB, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNOV, ZNTL, ACB, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNOV, ZNTL, ACB, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MNOV, ZNTL, ACB, and NMRA Company Descriptions

Aurora Cannabis NASDAQ:ACB

MediciNova NASDAQ:MNOV

Neumora Therapeutics NASDAQ:NMRA

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNOV, ZNTL, ACB, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNOV, ZNTL, ACB, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNOV, ZNTL, ACB, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MNOV, ZNTL, ACB, and NMRA Company Descriptions

Aurora Cannabis NASDAQ:ACB

MediciNova NASDAQ:MNOV

Neumora Therapeutics NASDAQ:NMRA

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools